Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher...

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Optimal treatment for restenosis after sirolimus-eluting stent (SES) implantation remains unclear.
• Restenosis is a significant complication following coronary stenting.

Purpose of the Study:

• To compare the effectiveness of repeated SES implantation versus balloon angioplasty (BA) for treating SES-associated restenosis.
• To evaluate the safety and long-term outcomes of these treatment strategies.

Main Methods:

• Analysis of the j-Cypher registry data involving 12,824 patients over 3 years.
• Comparison of recurrent target-lesion revascularization (TLR), stent thrombosis, and mortality rates between SES and BA treatment groups for restenosis.
• Multivariable logistic regression to identify risk factors for recurrent TLR.

Main Results:

• Cumulative incidence of recurrent TLR was significantly lower with SES (23.8%) compared to BA (37.7%) at 2 years post-first TLR (P<0.0001).
• Repeated SES implantation showed a strong treatment effect in preventing recurrent TLR (OR, 0.44; P<0.0001).
• No significant differences in 2-year mortality (10.4% vs 10.8%) or stent thrombosis (0.6% vs 0.6%) rates were observed between groups.

Conclusions:

• Repeated SES implantation is more effective than BA in preventing recurrent TLR for SES-associated restenosis.
• The use of repeated SES implantation demonstrates a favorable safety profile without increasing adverse events.